These tests are recommended by several well-established organizations in the field of medical oncology, such as ASCO, ESMO, or NCCN, but only for a specific group of early-stage breast cancers that are hormone receptor positive and sensitive to hormonal treatments. This evidence concerns the gene NR4A1 and breast cancer.